Frontiers in Psychiatry
June 24, 2026
Kathryn Fletcher, Nadine Ezard, Krista J. Siefried et al.
Background Methamphetamine use disorder (MAUD) is associated with substantial psychiatric and physical morbidity, and current treatment options remain limited. Ketamine-assisted psychotherapy (KAP) has shown promise in substance use disorders, but little is known about how individuals experience and interpret this intervention, particularly in MAUD. Qualitative investigation may provide insight...
Drug and Alcohol Review
March 1, 2026
Jack Freestone, Harriet MacDonald, Stassi Kypri et al.
Drug alerts are sometimes issued when samples are found to exceed a pre-determined dose threshold. In Australia, it is common for alerts to be issued when MDMA pills contain ≥ 150 mg of MDMA free-base or 179 mg hydrochloride. Nineteen such alerts were issued in Australia in 2024, raising concerns that repeat alerts may lose impact over time. This study examined experts' viewpoints on the...
Harm Reduction Journal
February 6, 2026
Keaton Hudson-Buhagiar, Jonathan Brett, Alanah Spillane et al.
1 citation
Harms associated with gamma-hydroxybutyrate (GHB) use have increased recently in Australia. However, research predominantly focuses on the experience of GHB use among LGBTQ + populations. Non-prescribed GHB use has not been well described in heterosexual populations. Research to examine the experience of heterosexual people, including motivations for use, experiences of harms, and utilisation...
BMJ Open
February 10, 2025
Kathryn Fletcher, Nadine Ezard, Krista J. Siefried et al.
1 citation
Methamphetamine use disorder is a significant public health concern. No pharmacological treatment options currently exist for methamphetamine use disorder, and psychotherapy is only moderately effective. Preliminary evidence suggests that ketamine-assisted psychotherapy produces sustained improvements in substance use and mental health symptomatology. In addition to direct antidepressant...